進階搜尋


 
系統識別號 U0026-0812200914145529
論文名稱(中文) 於非小細胞肺癌合併惡性肋膜積液中尋求潛在血管新生因子
論文名稱(英文) Potential Angiogenetic Biomarkers in Non-small Cell Lung Cancer with Malignant Pleural Effusion
校院名稱 成功大學
系所名稱(中) 臨床醫學研究所
系所名稱(英) Institute of Clinical Medicine
學年度 96
學期 2
出版年 97
研究生(中文) 許以霖
研究生(英文) I-Lin Hsu
學號 s9694115
學位類別 碩士
語文別 英文
論文頁數 31頁
口試委員 口試委員-呂佩融
召集委員-蘇五洲
指導教授-賴吾為
中文關鍵字 細胞間白 素8  基底纖維組織母細胞生長因子  血管內質細胞生長因子  二環氧酶  新生血管  惡性肋膜積液 
英文關鍵字 VEGF  bFGF  IL-8  COX-2  angiogenesis  malignant pleural effusion 
學科別分類
中文摘要 目的:評估非小細胞肺癌合併惡性肋膜積液的病患之潛在的新生血管因子生化標記,包括血管內質細胞生長因子(VEGF)、細胞間白素8(IL-8)、基底纖維組織母細胞生長因子(bFGF)、二環氧酶(COX-2) 設計:前瞻性研究 病患和方法:自1998年四月至2005年四月總共97位非小細胞肺癌合併惡性肋膜積液的病患,都於手術室接受全身麻醉及胸腔鏡手術。我們收集肋膜切片、肋膜積液及血液標本,以酵素連結免疫吸附分析(ELISA)及免疫組織化學染色分析新生血管因子。並收集病患的臨床資料及追蹤預後及肋膜積液控制。 結果:在臨床上,抽煙為存活的不佳因子,受限萎縮的肺臟為肋膜積液控制的不佳因子。而於基礎研究中發現血管內質細胞生長因子、細胞間白素8、基底纖維組織母細胞生長因子在肋膜積液及血液中濃度皆較高。但二環氧酶則否。血管內質細胞生長因子為間皮細胞及腫瘤細胞分泌。肋膜積液中血管內質細胞生長因子,和血液中的血管內質細胞生長因子、肋膜積液總量、肋膜積液紅血球數目有相關。肋膜積液中血管內質細胞生長因子濃度高於1350 ng/mL是存活及肋膜積液總量不佳的因素。而肋膜積液中細胞間白素8和血管內質細胞生長因子有低度相關。基底纖維組織母細胞生長因子則無相關。
結論: 於非小細胞肺癌合併惡性肋膜積液的病患中,新生血管因子:血管內質細胞生長因子、細胞間白素8、及基底纖維組織母細胞生長因子皆有表現。肋膜積液中血管內質細胞生長因子濃度高於1350 ng/mL是存活及肋膜積液總量不佳在統計學上有意義的預後因素。
英文摘要 Objective: To evaluate potential angiogenetic biomarkers, including vascular endothelial growth factor(VEGF), interleukin-8(IL-8), Basic fibroblast growth factor (bFGF), and cyclooxygenases-2 (COX-2) in non-small cell lung cancer with malignant pleural effusion (PE). Design: A prospective study Patients and methods: 97 patients of non-small cell lung cancer with malignant pleural effusion from April 1998 to April 2005 underwent general anesthesia and thoracoscopy in the operation room. The pleural specimen, pleural effusion and blood samples were collected to evaluate the angiogenetic factors with enzyme-linked immunosorbent assay (ELISA) and immunohistochemical staining. Clinical data were also collected and patients were followed up for survival and pleural effusion control. Results: Smoking is the poor prognostic factor of survival and trapped lung is the poor prognostic factor of pleural effusion control. VEGF, IL-8, and bFGF level were high in PE and sera but COX-2 was not. VEGF was secreted by mesothelial and tumor cells. PE VEGF correlated to serum VEGF, PE amount, and PE RBC number. PE VEGF>1350 ng/mL is the poor prognostic factor of PE amount and survival. PE IL-8 lowly correlated to PE VEGF. bFGF was not remarkable. Conclusions: Angiogenetic factors expressed (VEGF, IL-8, and bFGF) in patients of non-small lung cancer with malignant pleural effusion. PE VEGF level=1350 ng/mL is a significant predictor for more effusion and poor survival.
論文目次 總目錄 頁數
封面 1
考試合格證明 2
中文摘要 3-4
英文摘要 5
誌謝 6
總目錄 7
表目錄 8
圖目錄 9
緒論 10-11
病患及研究方法 12-13
結果 14-15
討論 16-17
結論 18
參考文獻 19-21
表附錄 22-24
圖附錄 25-30
作者著作目錄 31
參考文獻 Anderson CB, Philpott GW, Ferguson TB. The treatment of malignant pleural effusions. Cancer1974;33:916–922 Anderson IC, Mari SE, Broderick RJ, et al. The Angiogenic factor interleukin 8 is induced in non-small cell lung cancer/pulmonary fibroblast Cocultures. Cancer Res 2000;60:269-272
Boldrini L, Gisfredi S, Ursino S, et al. Interleukin-8 in non-small cell lung carcinoma: Relation with angiogenic pattern and p53 alterations. Lung Cancer 2005; 50: 309-317 Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer:The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood(Review). Lung Cancer 2006;51:143-158
Ceyhan BB, Ozgun S, Celikel T, Yalcin M, et al. IL-8 in pleural effusion. Respir Med 1996;90:215–221
Cox G, Jones JL, Walker RA, et al. Angiogenesis and non-small cell lung cancer. Lung Cancer 2000;27:81-100
Folkman J, Haudenschild C. Angiogenesis in vitro. Nature 1980;288:551-6 Grove CS, Gary Lee YC. Vascular endothelial growth factor:the key mediator in pleural effusion formation. Curr Opin Pulm Med 2002;14:357-363
Hamed EA, El-Noweihi AM, Mohamed AZ, et al. Vasoacitve mediators (VEGF and TNF-α) in paitents with malignant and tuberculous effusions. Resp 2004;9:81-86
Ishimoto O, Saijo Y, Narumi Ko, et al. High level of vascular endothelial growth factor in hemorrhagic pleural effusion of cancer. Oncol 2002;63:70–75
Koyama S, Sato E, Haniuda M, et al. Decreased level of vascular endothelial growth factor in bronchoalveolar lavage fluid of normal smokers and patients with pulmonary fibrosis. Am J Respir Crit Care Med 2002;166:382–385 Kuwano T, Nakao S, Yamamoto H, et al. Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. FASEB J 2004;18:300-10
Macchiarini P, Fontanini G, Hardin JM, et al. Relation of neovascularisation to metastasis of non-small cell lung cancer. Lancet 1992;340:145–146
Marrogi AJ, Travis WD, Welsh JA, et al. Nitric oxide synthase cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 2000;6:4739-44
Memon AN, Zawadzki ZA. Malignant effusions:diagnostic evaluation and therapeutic strategy (review). Curr Probl Cancer 1981;5:1–30
Michaud SE, Menard C, Guy LG, et al. Inhibition of hypoxia-induced angiogenesis by cigarette smoke exposure: impairment of the HIF-1_/VEGF pathway. FASEB J 2003;17:1150-1152 Pace E, Gjomarkaj
M, Melis M, et al. Interleukin-8 induces lymphocytes chemotaxis into the pleural space. Am J Respir Crit Care Med 1999;159:1592-1599
Reed, C. E. Management of the malignant pleural effusion. In: H. I.Pass, J. B. Mitchell, D. H. Johnson, and A. T. Turrisi (eds.), Lung Cancer: Principles and Practice, pp. 643–654. Philadelphia: Lippincott-Raven, 1996
Ruitz E, Aleman C, Alegre J, et al. Angiogenic factors and angiogenesis inhibitors in exudative pleural effusions. Lung 2005;183:185-195
Sakao S, Tatsumi K, Hashimoto T, et al. Vascular endothelial growth factor and the risk of smoking-related COPD. Chest 2003;124:323-327.
Singhal S, Vachni A, Danielle AO, et al. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer:a review. Clin Cancer Res 2005;11:3974-3986
Stinchcombe TE , Socinski MA. Bevacizumab in the treatment of non-small-cell lung cancer(review). Oncogene 2007;26:3691–3698
Su WC, Lai WW, Helen HW, et al. Combined intrapleural and intravenous chemotherapy, and pulmonary irradiation,for treatment of patients with lung cancer presenting with malignant pleural effusion. Oncol 2003;64:18-24
Tan C, Sedrakyan A, Browne J, et al. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg 2006;29:829-833
Tas F, Duranyildiz D, Oguz H, et al. Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer. Cancer Invest 2006;24:492-496 Thickett DR, Armstrong L, Millar AB: Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax 1999;54:707–710 Walker-Renard PB, Vaughan LM, Sahn SA. Chemical pleurodesis for malignant pleural effusions(review). Ann Intern Med 1994;120:56–64
Yanagawa H, Takeuchi E, Suzuki Y, et al. Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer. Cancer Immunol Immunother 1999;48:396–400
Yano S, Herbst RS, Shinohara H, et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor Receptor Tyrosine kinase phosphorylation. Clin Cancer Res 2000;6:957-965
Zebrowski BK, Yano S, Liu W, et al. Vascular endothelial growth factor levels and induction permeability in malignant pleural effusions. Clin Cancer Res 1995;5:3364–3368
論文全文使用權限
  • 同意授權校內瀏覽/列印電子全文服務,於2009-07-10起公開。
  • 同意授權校外瀏覽/列印電子全文服務,於2009-07-10起公開。


  • 如您有疑問,請聯絡圖書館
    聯絡電話:(06)2757575#65773
    聯絡E-mail:etds@email.ncku.edu.tw